Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aarti PharmalabsNSE:AARTIPHARM -1.06%56 EV-to-EBITDA is 17.11 as of Aug. 02, 2026, which is 20% above its 10-year median of 14.26. GuruFocus rates NSE:AARTIPHARM with a GF Score™ of 56/100 and a GF Value™ of ₹648.04 (Fairly Valued). The stock has 3 warning signs investors should review. Among 746 Drug Manufacturers companies, Aarti Pharmalabs ranks worse than 62.47% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aarti Pharmalabs's enterprise value is ₹68,416 Mil.
Aarti Pharmalabs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹3,999 Mil. Therefore, Aarti Pharmalabs's EV-to-EBITDA for today is 17.11.
The historical rank and industry rank for Aarti Pharmalabs's EV-to-EBITDA or its related term are showing as below:
NSE:AARTIPHARM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.67 Med: 14.26 Max: 19.25
Current: 17.11
During the past 6 years, the highest EV-to-EBITDA of Aarti Pharmalabs was 19.25. The lowest was 7.67. And the median was 14.26.
NSE:AARTIPHARM's EV-to-EBITDA is ranked worse than 62.47% of 746
companies
in the Drug Manufacturers industry
Industry Median: 12.995
vs NSE:AARTIPHARM: 17.11
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aarti Pharmalabs's PE Ratio (TTM) for today is calculated as:
Aarti Pharmalabs's share price for today is ₹667.15.
Aarti Pharmalabs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹20.570.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Aarti Pharmalabs's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Pharmalabs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aarti Pharmalabs EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aarti Pharmalabs's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aarti Pharmalabs's EV-to-EBITDA falls into.
Aarti Pharmalabs's current Enterprise Value is ₹68,416 Mil.
Aarti Pharmalabs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3,999 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aarti Pharmalabs (NSE:AARTIPHARM) has a EV-to-EBITDA of 17.11 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aarti Pharmalabs. This is 20% above median its historical median of 14.26. Over the past decade, Aarti Pharmalabs' EV-to-EBITDA has ranged from 7.67 to 19.25. According to the industry distribution chart, Aarti Pharmalabs ranks #466 out of 746 companies in the Drug Manufacturers industry, placing it in the top 62.5%.
Is Aarti Pharmalabs' EV-to-EBITDA too high?
Aarti Pharmalabs' current EV-to-EBITDA of 17.11 is 20% above median its 10-year median of 14.26. Over the past 10 years, this metric has ranged from a low of 7.67 to a high of 19.25. The Drug Manufacturers industry median EV-to-EBITDA is 13.00. Aarti Pharmalabs' value of 17.11 is 31.7% above this industry median. Based on the distribution chart, Aarti Pharmalabs ranks #466 out of 746 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aarti Pharmalabs has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aarti Pharmalabs' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Aarti Pharmalabs ranks #466 out of 746 companies for EV-to-EBITDA. This places Aarti Pharmalabs in the lower half of its industry. The industry median EV-to-EBITDA is 13.00. Aarti Pharmalabs' value of 17.11 is 31.7% above this benchmark. Historically, Aarti Pharmalabs' own EV-to-EBITDA has ranged from 7.67 to 19.25 over the past decade. While the company's 10-year median is 14.26 vs. the industry median of 13.00, Aarti Pharmalabs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.00, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aarti Pharmalabs's current EV-to-EBITDA of 17.11 is 31.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aarti Pharmalabs. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aarti Pharmalabs's current EV-to-EBITDA is 17.11, which is 20% above median its own 10-year median of 14.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Pharmalabs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Pharmalabs (NSE:AARTIPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹648.04, compared to a current price of ₹667.15 — trading 2.9% above its estimated fair value. The current EV-to-EBITDA is 17.11, which is 20% above median its 10-year median of 14.26 and 31.7% above the Drug Manufacturers industry median of 13.00. Aarti Pharmalabs' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Aarti Pharmalabs (NSE:AARTIPHARM), the current EV-to-EBITDA is 17.11 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aarti Pharmalabs (NSE:AARTIPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued.
The current stock price of ₹667.15 is trading 2.9% above its estimated GF Value™ of ₹648.04.
GuruFocus considers Aarti Pharmalabs to be Fairly Valued.
Key valuation signals for NSE:AARTIPHARM:
EV-to-EBITDA: 17.11 (20% above median its 10-year median of 14.26)
GF Value™: ₹648.04 vs. price of ₹667.15 (2.9% above fair value)
Industry Position: 31.7% above the Drug Manufacturers median (#466 of 746)
No single metric tells the full story. See the NSE:AARTIPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
56GF Score
Get the complete analysis for NSE:AARTIPHARM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AARTIPHARM has been successfully added to your 
